{'fraction_non_alphanumeric': 0.03486238532110092, 'fraction_numerical': 0.005504587155963303, 'mean_word_length': 5.7407407407407405, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Daclizumab high‐yield process reduced the evolution of new gadolinium‐enhancing lesions to T1 black holes in patients with relapsing−remitting multiple sclerosis

In the SELECT study, treatment with daclizumab high‐yield process (DAC HYP) versus placebo reduced the frequency of gadolinium‐enhancing (Gd+) lesions in patients with relapsing−remitting multiple sclerosis (RRMS). The objective of this post hoc analysis of SELECT was to evaluate the effect of DAC HYP on the evolution of new Gd+ lesions to T1 hypointense lesions (T1 black holes).